8-K: Corvus Pharma Advances Soquelitinib, Reports Q3 2025 Results

Corvus Pharmaceuticals provided a business update and reported third-quarter 2025 financial results, highlighting progress in its soquelitinib clinical programs for atopic dermatitis and T cell lymphoma.

Summary

• Completed enrollment in extension cohort 4 of the soquelitinib atopic dermatitis Phase 1 clinical trial (200 mg BID dose with 8-week treatment period), with data announcement anticipated in January 2026.
• The soquelitinib atopic dermatitis Phase 2 trial is on track to initiate in early Q1 2026, anticipated to enroll approximately 200 patients with moderate-to-severe atopic dermatitis.
• The Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) is actively enrolling patients at multiple clinical sites, evaluating soquelitinib versus physician's choice.
• Final results from the Phase 1/1b clinical trial evaluating soquelitinib in T cell lymphoma have been accepted for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025.
• Cash, cash equivalents and marketable securities totaled $65.7 million as of September 30, 2025, an increase from $52.0 million as of December 31, 2024.
• Cash is expected to fund operations into the fourth quarter of 2026.
• Research and development expenses for the three months ended September 30, 2025, were $8.5 million, up from $5.2 million for the same period in 2024, primarily due to higher clinical trial and manufacturing costs.
• Net loss for the three months ended September 30, 2025, was $10.2 million, significantly lower than the $40.2 million net loss for the same period in 2024, primarily due to a non-cash loss of $32.8 million in Q3 2024 related to warrant liability fair value change.

Sentiment

Score: 7

Explanation: The company reported solid progress in its clinical development programs for soquelitinib, including completed enrollment in a key Phase 1 cohort and being on track for Phase 2 initiation, alongside active enrollment in a registrational Phase 3 trial. The cash runway into Q4 2026 provides financial stability. While R&D expenses increased, this is expected for advancing programs. The net loss reduction was largely due to a non-cash item, but overall, the operational updates are positive for a clinical-stage biotech.

Positives

• Completed enrollment in extension cohort 4 of the soquelitinib atopic dermatitis Phase 1 clinical trial, a key development milestone.
• Soquelitinib atopic dermatitis Phase 2 clinical trial is on track to initiate in early Q1 2026, indicating consistent progress.
• The registrational Phase 3 clinical trial of soquelitinib in relapsed/refractory PTCL is actively enrolling patients, advancing towards potential approval.
• Final Phase 1/1b data for soquelitinib in T cell lymphoma accepted for oral presentation at ASH, suggesting promising prior results.
• Cash, cash equivalents and marketable securities increased to $65.7 million as of September 30, 2025, from $52.0 million at December 31, 2024.
• Cash is expected to fund operations into the fourth quarter of 2026, providing a solid financial runway.
• Net loss for Q3 2025 significantly decreased to $10.2 million from $40.2 million in Q3 2024, although largely due to a non-cash item.
• Soquelitinib has received Orphan Drug Designation and Fast Track designation for the treatment of T cell lymphoma, potentially accelerating development and review.

Negatives

• Research and development expenses increased to $8.5 million in Q3 2025 from $5.2 million in Q3 2024, indicating a higher operational burn rate.
• The company continues to report a net loss, totaling $10.2 million for Q3 2025.
• There are no FDA fully approved agents for the treatment of relapsed/refractory PTCL based on randomized trials, highlighting the high development risk despite the unmet need.

Risks

• Ability to demonstrate sufficient evidence of efficacy and safety in clinical trials of product candidates.
• Accuracy of estimates relating to the ability to initiate and/or complete preclinical studies and clinical trials and release data.
• Results of preclinical studies and interim data from clinical trials may not be predictive of future results.
• Ability to enroll sufficient numbers of patients in clinical trials.
• Unpredictability of the regulatory process in the United States and foreign countries.
• Clinical trial costs may exceed expectations.
• Ability to accurately estimate the cash on hand providing funding into the fourth quarter of 2026.
• Ability to raise additional capital.

Future Outlook

The company anticipates announcing data from the soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 in January 2026 and is on track to initiate the Phase 2 trial in early Q1 2026. Enrollment continues for the registrational Phase 3 clinical trial of soquelitinib in relapsed/refractory PTCL. Cash is expected to fund operations into the fourth quarter of 2026, and the company continues to advance its next-generation ITK inhibitor preclinical product candidates.

Management Comments

• "We are advancing the development of our ITK inhibitor, soquelitinib, in both atopic dermatitis and T cell lymphomas. We believe soquelitinib has the potential to be ideally positioned as a well-tolerated treatment for a range of immune diseases and cancers that works through a novel mechanism of action." Richard A. Miller, M.D., co-founder, president and chief executive officer.
• "We look forward to reporting results from extension cohort 4 of the soquelitinib Phase 1 trial in atopic dermatitis in the coming months, which will provide additional information on the 200 mg twice daily dose and a longer 8-week treatment period." Richard A. Miller, M.D., co-founder, president and chief executive officer.
• "In addition, we remain on track to initiate an atopic dermatitis Phase 2 trial with soquelitinib in early Q1 2026." Richard A. Miller, M.D., co-founder, president and chief executive officer.
• "In oncology, our Phase 3 registration clinical trial in PTCL continues to enroll and we are pleased that the final results from the related Phase 1/1b trial will be presented in an oral session at ASH. These data add to the growing clinical evidence supporting soquelitinib as a safe and active agent with potential in a range of diseases." Richard A. Miller, M.D., co-founder, president and chief executive officer.

Industry Context

Corvus Pharmaceuticals is positioned in the competitive biopharmaceutical sector, developing a novel ITK inhibitor, soquelitinib, for both immunology (atopic dermatitis, ALPS) and oncology (T cell lymphoma). The focus on a novel mechanism of action could offer differentiation. The PTCL market represents a high unmet medical need with no FDA fully approved agents based on randomized trials, offering a significant market opportunity if soquelitinib is successful. Atopic dermatitis is a large market with existing treatments, indicating a need for differentiated and effective new therapies.

Comparison to Industry Standards

• The company is addressing a significant unmet medical need in relapsed/refractory PTCL, where there are no FDA fully approved agents based on randomized trials, and current treatments offer poor outcomes with median progression-free survival of 3-4 months and overall median survival of 6-12 months.
• The cash runway into Q4 2026 is a positive indicator of financial stability, providing a longer operational period compared to many early-stage biotechs that often require more frequent capital raises.
• The increase in R&D expenses is consistent with industry standards for a clinical-stage biopharmaceutical company advancing multiple drug candidates into later-stage trials, reflecting necessary investment in development.

Related Party Transactions

• Corvus Pharmaceuticals holds a 49.7% equity stake in Angel Pharmaceuticals (excluding 7% reserved for employee stock ownership plan) and has designated three individuals on Angel's five-person Board of Directors.
• Angel Pharmaceuticals licensed the rights to develop and commercialize Corvus's three clinical-stage candidates (soquelitinib, ciforadenant, and mupadolimab) in greater China and obtained global rights to Corvus's BTK inhibitor preclinical programs.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful, but also risk of dilution if additional capital is needed. Positive clinical updates and extended cash runway provide some confidence.
• Patients: Potential for new treatment options for atopic dermatitis, peripheral T cell lymphoma, and Autoimmune Lymphoproliferative Syndrome (ALPS), especially given the high unmet need in PTCL.
• Employees: Continued employment and potential for growth as clinical programs advance.
• Partners (NIAID, Angel Pharmaceuticals): Continued collaboration on clinical trials and development programs.

Next Steps

• Announce data from soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 in January 2026.
• Initiate soquelitinib atopic dermatitis Phase 2 clinical trial in early Q1 2026.
• Continue enrolling patients in the registrational Phase 3 clinical trial of soquelitinib in relapsed/refractory PTCL.
• Present final data from Phase 1/1b clinical trial for soquelitinib in T cell lymphoma at the 67th ASH Annual Meeting in December 2025.
• Continue advancing next-generation ITK inhibitor preclinical product candidates.

Key Dates

Recommendation

Corvus Pharmaceuticals is making steady progress in its clinical pipeline, particularly with soquelitinib in both atopic dermatitis and PTCL, including a registrational Phase 3 trial. The extended cash runway into Q4 2026 provides a good financial buffer. However, as a clinical-stage biopharmaceutical company, significant risks remain regarding trial outcomes, regulatory approvals, and the need for future capital. While the clinical updates are positive, they are largely "on track" or "completed enrollment" rather than breakthrough efficacy data. The stock is likely to be volatile based on upcoming data readouts. A "hold" recommendation reflects the positive operational momentum and financial stability balanced against the inherent high risks of drug development.

Keywords

Soquelitinib, ITK inhibitor, Atopic Dermatitis, Peripheral T Cell Lymphoma, PTCL, Oncology, Immunology, Clinical Trials, Biopharmaceutical, Corvus Pharmaceuticals, CRVS, Orphan Drug, Fast Track, ASH, NIAID, ALPS